Contact
searchSearch
HMP Global
Login

Prostate Cancer Specialty Channel

News
Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases
08/19/2025
Stephanie Holland
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the...
08/19/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
News
NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer
08/05/2025
Allison Casey
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may...
08/05/2025
Oncology
FDA Approval
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
06/03/2025
Stephanie Holland
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the...
06/03/2025
Oncology
Conference Coverage
Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer
06/02/2025
Emily Estrada
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial...
06/02/2025
Oncology
News
Addition of Pembrolizumab Fails to Improve Outcomes for Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
05/28/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3...
05/28/2025
Oncology
News
Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Fails to Improve Survival for Patients With Metastatic Hormone-Sensitive Prostate Cancer
05/20/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the...
05/20/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
Neeraj Agarwal, MD
Conference Coverage
Talazoparib Plus Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
03/03/2025
Neeraj Agarwal, MD
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-2 trial which demonstrated that first-line talazoparib plus enzalutamide improved overall survival among patients with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-2 trial which demonstrated that first-line talazoparib plus enzalutamide improved overall survival among patients with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, discusses...
03/03/2025
Oncology
Michael Schweizer, MD
Conference Coverage
Mevrometostat Plus Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
03/03/2025
Michael Schweizer, MD
Michael Schweizer, MD, discusses results from a dose-expansion study which demonstrated that the addition of mevrometostat to enzalutamide improved outcomes among patients with metastatic castration-resistant prostate cancer.
Michael Schweizer, MD, discusses results from a dose-expansion study which demonstrated that the addition of mevrometostat to enzalutamide improved outcomes among patients with metastatic castration-resistant prostate cancer.
Michael Schweizer, MD, discusses...
03/03/2025
Oncology

News

News
Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases
08/19/2025
Stephanie Holland
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the...
08/19/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
News
NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer
08/05/2025
Allison Casey
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may...
08/05/2025
Oncology
FDA Approval
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
06/03/2025
Stephanie Holland
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the...
06/03/2025
Oncology
Conference Coverage
Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer
06/02/2025
Emily Estrada
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial...
06/02/2025
Oncology
News
Addition of Pembrolizumab Fails to Improve Outcomes for Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
05/28/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3...
05/28/2025
Oncology
News
Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Fails to Improve Survival for Patients With Metastatic Hormone-Sensitive Prostate Cancer
05/20/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the...
05/20/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
Neeraj Agarwal, MD
Conference Coverage
Talazoparib Plus Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
03/03/2025
Neeraj Agarwal, MD
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-2 trial which demonstrated that first-line talazoparib plus enzalutamide improved overall survival among patients with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-2 trial which demonstrated that first-line talazoparib plus enzalutamide improved overall survival among patients with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, discusses...
03/03/2025
Oncology

Interactive Features

Quiz
Improving Detection of Clinically Significant Prostate Cancer
01/15/2024
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the...
01/15/2024
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Quiz
Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
11/02/2022
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found...
11/02/2022
Oncology
Quiz
Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer
09/02/2022
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating...
09/02/2022
Oncology
Quiz
Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?
07/21/2022
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available...
07/21/2022
Oncology
Test Your Knowledge
Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?
09/02/2021
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with...
09/02/2021
Oncology
Test Your Knowledge
Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?
07/29/2021
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small...
07/29/2021
Oncology
Test Your Knowledge
Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?
07/29/2021
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?
Which treatment approach...
07/29/2021
Oncology

Recent News

News
Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases
08/19/2025
Stephanie Holland
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the...
08/19/2025
Oncology
News
NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer
08/05/2025
Allison Casey
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.
NRG1 levels prior to ADT may...
08/05/2025
Oncology
FDA Approval
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
06/03/2025
Stephanie Holland
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the ARANOTE study, the FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer.
Based on results from the...
06/03/2025
Oncology
Conference Coverage
Lower-Dose Abiraterone Non-Inferior to Standard Dose for Metastatic Castration-Resistant Prostate Cancer
06/02/2025
Emily Estrada
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial showed lower-dose abiraterone acetate demonstrates comparable efficacy and safety to standard dosing for the treatment of metastatic castration-resistant prostate cancer.
A phase 3 non-inferiority trial...
06/02/2025
Oncology
News
Addition of Pembrolizumab Fails to Improve Outcomes for Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
05/28/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3 KEYNOTE-641 study demonstrated that the addition of pembrolizumab to enzalutamide did not improve outcomes among chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Results from the phase 3...
05/28/2025
Oncology
News
Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy Fails to Improve Survival for Patients With Metastatic Hormone-Sensitive Prostate Cancer
05/20/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the phase 3 KEYNOTE-991 study, pembrolizumab plus enzalutamide and continuous androgen deprivation therapy did not improve survival results among patients with metastatic hormone-sensitive prostate cancer.
According to results from the...
05/20/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
Conference Coverage
Addition of Mevrometostat Improves Outcomes for Patients With Metastatic Castration-Resistant Prostate Cancer
02/13/2025
Stephanie Holland
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion...
02/13/2025
Oncology
Conference Coverage
First-Line Talazoparib Plus Enzalutamide Improves Survival for Patients With Metastatic Castration-Resistant Prostate Cancer
02/13/2025
Stephanie Holland
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3...
02/13/2025
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use